The Canton of Solothurn had a valuation report prepared for its hospitals
The Canton of Solothurn is the owner of Solothurner Spitäler AG (soH), with its three hospitals in Solothurn, Olten and Dornach.
As part of its audit work, the Solothurn Cantonal Audit Office, as external auditors, had a second opinion prepared, which answers various questions in connection with soH’s annual impairment test and other valuation questions.
The Oaklins team in Switzerland was able to draw on its longstanding experience and profound expertise in valuation topics for this challenging assignment. It conducted the relevant valuation analyses, interviewed management and external stakeholders and answered and documented the specific questions in a comprehensive report.
Gabrielle Rudolf von Rohr
Head of the Cantonal Audit Office, Solothurn
Contacter l'équipe de la transaction
Daniel Eichenberger
Oaklins Switzerland
Transactions connexes
EuroHospital Varna has been acquired by Intermedica Group
EuroHospital Varna has been acquired by Intermedica Group, allowing the business to continue to grow and deliver high-quality healthcare services to its patients. Through the transaction, Intermedica Group expands its healthcare presence and intends to build a new model of integrated personalized care focused on preventive, holistic and digital medicine.
En apprendre plusMEDIK Hospital Design Group has been acquired by STERIS
The private shareholders of MEDIK Hospital Design Group have sold their shares to STERIS plc. Together, MEDIK and STERIS will expand their offerings for hospitals and ambulatory surgery centers worldwide. MEDIK’s solutions ideally complement STERIS’ existing portfolio, enabling the combined group to strengthen its position as a leading provider of turnkey room solutions in surgical and IPT environments. The MEDIK management team will actively support the next phase of growth.
En apprendre plusbioXXmed AG has sold Rancoderm GmbH to Rose Investment- und Beteiligungs AG
Rancoderm GmbH has been acquired by Rose Investment- und Beteiligungs AG to secure the funding required for the final development and market approval of its medical device DermaPro. The acquisition will enable Rancoderm to bring DermaPro to market readiness and launch it as a certified medical product for broad distribution.
En apprendre plus